Hepatitis Treatments and Vaccines: World Market 2012-2022
How to find trends and revenue prospects for hepatitis-treating agents
Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.
You see forecasting of therapeutic submarkets to 2022, finding potential revenues:
You also find revenue forecasting of product classes to 2022:
How will 10 leading products - including Baraclude, Pegasys, Incivek and PegIntron - perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.
The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.
Market value for 2012 and prospects for the future
What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.
We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.
What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.
The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.
High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.
Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.
Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.
Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for the treatment and prevention of hepatitis
Our study is for everybody needing industry and market analyses for hepatitis-treating drugs and vaccines. You find data, trends and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.
You see forecasting of therapeutic submarkets to 2022, finding potential revenues:
- Hepatitis B
- Hepatitis C.
You also find revenue forecasting of product classes to 2022:
- Oral antivirals
- Interferons
- Vaccines.
How will 10 leading products - including Baraclude, Pegasys, Incivek and PegIntron - perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.
The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.
Market value for 2012 and prospects for the future
What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.
We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.
What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.
The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.
High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.
Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.
Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.
Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
- Find potential revenues to 2022 for the world market and submarkets
- Discover projected revenue trends of 10 leading brands to 2022
- See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
- Assess 7 leading companies, and other players, discovering activities and outlooks
- Review R&D pipelines, seeing trends by therapeutic area
- Investigate competition and opportunities influencing sales
- Find out what will stimulate and restrain the industry and market
- View opinions from the sector, seeing an interview with an external authority.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for the treatment and prevention of hepatitis
Our study is for everybody needing industry and market analyses for hepatitis-treating drugs and vaccines. You find data, trends and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. EXECUTIVE SUMMARY
1.1 Hepatitis Treatments and Vaccines: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO HEPATITIS
2.1 Hepatitis: A Brief Overview
2.1.1 Symptoms and Diagnosis
2.1.2 Hepatitis B
2.1.2.1 Hepatitis D
2.1.3 Hepatitis C
2.1.4 Hepatitis A
2.1.5 Hepatitis E
2.2 Risk Factors for Hepatitis
2.3 Recent Trends in Incidence and Prevalence
2.4 Hepatitis: Treatment and Prevention
2.4.1 Antiviral Therapy
2.4.1.1 Treatment with Interferon and Ribavirin
2.4.2 Vaccines
2.4.2.1 Hepatitis E Vaccine
3. THE WORLD HEPATITIS TREATMENT AND VACCINE MARKET 2012-2022
3.1 The Hepatitis Treatment and Vaccine Market 2011
3.1.1 The Hepatitis Treatment Market by Indication
3.2 The Hepatitis Treatment and Vaccine Market: Overall Revenue Forecast 2012-2022
3.2.1 Rising Awareness and Screening
3.2.2 Generic Competition in the Hepatitis B Treatment Market
3.2.3 Biosimilar Interferons
3.2.4 Rise of Direct-Acting Antivirals (DAAs)
3.3 Oral Antivirals Submarket 2011
3.3.1 DAAs in Hepatitis B
3.3.2 DAAs in Hepatitis C
3.3.3 Oral Antivirals Submarket: Revenue Forecast 2012-2022
3.3.4 A Long Pipeline
3.3.5 All-Oral Treatment for Hepatitis C
3.4 Interferons Submarket 2011
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2011
3.4.4 Interferons Submarket: Revenue Forecast 2012-2022
3.4.5 Next Generation Interferons in Development
3.5 Hepatitis Vaccines Submarket 2011
3.5.1 GSK: A Dominant Global Player
3.5.2 Expanding Vaccination Programmes in Emerging Markets
3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast 2012-2022
3.6 Hepatitis Treatment and Vaccine Submarket Shares 2011, 2016 and 2022
3.7 Hepatitis Treatment Market: Revenue Forecast by Indication 2012-2022
4. LEADING NATIONAL HEPATITIS TREATMENT AND VACCINE MARKETS 2012-2022
4.1 Global Prevalence of Hepatitis 2012
4.1.1 The Importance of Asia
4.2 Hepatitis Treatment and Vaccine Market: Regional Breakdown 2011
4.3 Hepatitis Treatment and Vaccine Market: Regional Forecast 2012-2022
4.4 The US
4.4.1 Population Movement and Hepatitis
4.4.2 Screening for Hepatitis
4.4.3 The US: Revenues 2012-2022
4.5 Europe
4.5.1 Regional Prevalence
4.5.2 European Market 2011
4.5.3 European Market: Revenue Forecasts 2012-2022
4.5.4 Italy: Revenues 2012-2022
4.5.5 Spain: Revenues 2012-2022
4.5.6 Germany: Revenues 2012-2022
4.5.7 UK: Revenues 2012-2022
4.5.8 France: Revenues 2012-2022
4.6 Hepatitis in Asia
4.7 China
4.7.1 Increased Vaccination
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenues 2012-2022
4.8 Japan
4.8.1 Hepatitis B and C in Japan
4.8.2 Japan: Revenues 2012-2022
4.9 India
4.9.1 Low Awareness and Vaccination Rates
4.9.2 India: Revenues 2012-2022
5. LEADING HEPATITIS THERAPIES: MARKET PROSPECTS TO 2022
5.1 Leading Hepatitis B Therapies 2012-2022
5.2 Baraclude (Bristol-Myers Squibb)
5.2.1 Recent Revenue Analysis
5.2.2 Patent Challenges
5.2.3 Baraclude: Revenue Forecast 2012-2022
5.3 Zeffix (GSK)
5.3.1 Recent Revenue Analysis
5.3.2 Resistance to Zeffix
5.3.3 Generic Competition
5.3.4 Zeffix: Revenue Forecast 2012-2022
5.4 Hepsera (Gilead Sciences/GSK)
5.4.1 Recent Revenue Analysis
5.4.2 Patent Expiry and Generic Competition
5.4.3 Switching to Viread
5.4.4 Hepsera: Revenue Forecast 2012-2022
5.5 Viread (Gilead Sciences)
5.5.1 Recent Revenue Analysis
5.5.2 GSK Licensing Agreement
5.5.3 Prodrugs in Development
5.5.4 Viread: Revenue Forecast 2012-2022
5.6 Tyzeka (Novartis)
5.6.1 Resistance and Competition
5.6.2 Tyzeka: Revenue Forecast 2012-2022
5.7 Leading Hepatitis B Vaccines 2012-2022
5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
5.8.1 Recent Revenue Analysis
5.8.2 Demand and Supply in Emerging Markets
5.8.3 Competition in the Pipeline
5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast 2012-2022
5.9 Leading Hepatitis C Therapies 2012-2022
5.10 Pegasys (Roche)
5.10.1 Recent Revenue Analysis
5.10.2 Label Expansions and Lifecycle Management
5.10.3 Pegasys: Revenue Forecast 2012-2022
5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
5.11.1 Revenue Analysis 2011
5.11.2 Possible Label Expansion
5.11.3 Incivek in Interferon-Free Regimens
5.11.4 Pipeline Competition
5.11.5 Incivek: Revenue Forecast 2012-2022
5.12 PegIntron (Merck & Co.)
5.12.1 Revenue Analysis 2011
5.12.2 Biosimilar Competition
5.12.3 Lifecycle Management
5.12.4 PegIntron: Revenue Forecast 2012-2022
5.13 Victrelis (Merck & Co.)
5.13.1 Revenue Analysis 2011
5.13.2 Roche Collaboration
5.13.3 Product Differentiation
5.13.4 Victrelis: Revenue Forecast 2012-2022
6. HEPATITIS TREATMENT AND VACCINE MARKET: LEADING PIPELINE CANDIDATES 2012
6.1 Leading Hepatitis C Pipeline Candidates 2012
6.1.1 Alisporivir (Novartis/Debiopharm)
6.1.2 BI 201335 (Boehringer Ingelheim)
6.1.2.1 BI 207127 (Boehringer Ingelheim)
6.1.3 Daclatasvir (Bristol-Myers Squibb)
6.1.3.1 Asunaprevir (Bristol-Myers Squibb)
6.1.4 GS-7977 (Gilead Sciences)
6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir)
6.1.5.1 TMC435 in All-Oral Regimens
6.1.6 Vaniprevir (Merck & Co.)
6.1.7 ABT-450 (Abbott Laboratories)
6.1.8 ACH-1625 (Achillion Pharmaceuticals)
6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals)
6.1.10 Danoprevir (Roche)
6.1.11 GI-5005 (GlobeImmune)
6.1.12 IDX184 (Idenix Pharmaceuticals)
6.1.13 INX-189 (Inhibitex)
6.1.14 Locteron (Biolex)
6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb)
6.1.16 R7128 (Roche/Pharmasset)
6.1.17 SCY-635
6.1.18 Setrobuvir (Roche)
6.1.19 Tegobuvir (Gilead Sciences)
6.1.20 VX-222 (Vertex Pharmaceuticals)
6.2 Leading Hepatitis B Pipeline Candidates 2012
6.2.1 Heplisav (Dynavax Technologies)
6.2.2 Rep 9AC' (REPLICor)
6.2.3 Myrcludex B (MYR)
6.2.4 AGX-1009 (Agenix)
7. LEADING COMPANIES IN HEPATITIS TREATMENT IN 2012
7.1 Leading Market Players, 2012
7.2 Roche
7.2.1 Product Overview and Performance 2011
7.2.2 Recent Developments
7.2.3 Hepatitis Pipeline
7.2.4 Future Outlook
7.3 GSK
7.3.1 Product Overview and Performance 2011
7.3.2 Recent Developments
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook
7.4 Bristol-Myers Squibb
7.4.1 Product Overview and Performance 2011
7.4.2 Recent Developments
7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook
7.5 Merck & Co.
7.5.1 Product Overview and Performance 2011
7.5.2 Recent Developments
7.5.3 Hepatitis Pipeline
7.5.4 Future Outlook
7.6 Vertex Pharmaceuticals
7.6.1 Product Overview and Performance 2011
7.6.2 Recent Developments
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook
7.7 Gilead Sciences
7.7.1 Product Overview and Performance 2011
7.7.2 Gilead Acquires Pharmasset
7.7.3 Hepatitis Pipeline
7.7.4 Future Outlook
7.8 Novartis
7.8.1 Product Overview and Performance 2011
7.8.2 Recent Developments
7.8.3 Hepatitis Pipeline
7.8.4 Future Outlook
7.9 Leading Hepatitis Pipeline Companies
7.9.1 Abbott Laboratories
7.9.2 Achillion Pharmaceuticals
7.9.2.1 Achillion and Gilead
7.9.3 Boehringer Ingelheim
7.9.4 Idenix Pharmaceuticals
7.9.4.1 Idenix Pharmaceuticals: Outlook
8. HEPATITIS TREATMENT AND VACCINE MARKET: INDUSTRY TRENDS 2012-2022
8.1 Strengths and Weaknesses in the Hepatitis Treatment and Vaccine Market 2011
8.1.1 Resistance in Hepatitis B
8.1.2 Interferon Therapy Has Drawbacks
8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis Treatment and Vaccine Market 2012-2022
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 Hepatitis B Vaccination
8.4 Limited Hepatitis B Pipeline
8.5 Hepatitis C Vaccines
8.6 Oral Direct-Acting Antivirals
8.6.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.6.2 Combining Protease and Polymerase Inhibitors
8.6.3 The Need for Ribavirin
8.6.4 Twelve Week Treatment Target
8.7 Pharmaceutical Investment in Hepatitis C
8.7.1 Licensing and Partnering Deals
8.7.2 Acquisitions in Hepatitis C
8.7.3 Future Targets for Collaboration or Acquisition
9. RESEARCH INTERVIEW
9.1 Dr David Spencer, CEO, Biotechnology Enterprise Management
9.1.1 Novel Interferon Development
9.1.2 Performance in a Competitive Market
9.1.3 Biosimilar Interferons
9.1.4 Opportunities and Threats in the Hepatitis C Market
10. CONCLUSIONS
10.1 State of the Hepatitis Treatment and Vaccine Market 2011
10.2 Growth in the Hepatitis Treatment and Vaccine Market 2012-2022
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Weak Pipeline for Hepatitis B
10.3 Asia as a Hepatitis Market
1.1 Hepatitis Treatments and Vaccines: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO HEPATITIS
2.1 Hepatitis: A Brief Overview
2.1.1 Symptoms and Diagnosis
2.1.2 Hepatitis B
2.1.2.1 Hepatitis D
2.1.3 Hepatitis C
2.1.4 Hepatitis A
2.1.5 Hepatitis E
2.2 Risk Factors for Hepatitis
2.3 Recent Trends in Incidence and Prevalence
2.4 Hepatitis: Treatment and Prevention
2.4.1 Antiviral Therapy
2.4.1.1 Treatment with Interferon and Ribavirin
2.4.2 Vaccines
2.4.2.1 Hepatitis E Vaccine
3. THE WORLD HEPATITIS TREATMENT AND VACCINE MARKET 2012-2022
3.1 The Hepatitis Treatment and Vaccine Market 2011
3.1.1 The Hepatitis Treatment Market by Indication
3.2 The Hepatitis Treatment and Vaccine Market: Overall Revenue Forecast 2012-2022
3.2.1 Rising Awareness and Screening
3.2.2 Generic Competition in the Hepatitis B Treatment Market
3.2.3 Biosimilar Interferons
3.2.4 Rise of Direct-Acting Antivirals (DAAs)
3.3 Oral Antivirals Submarket 2011
3.3.1 DAAs in Hepatitis B
3.3.2 DAAs in Hepatitis C
3.3.3 Oral Antivirals Submarket: Revenue Forecast 2012-2022
3.3.4 A Long Pipeline
3.3.5 All-Oral Treatment for Hepatitis C
3.4 Interferons Submarket 2011
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2011
3.4.4 Interferons Submarket: Revenue Forecast 2012-2022
3.4.5 Next Generation Interferons in Development
3.5 Hepatitis Vaccines Submarket 2011
3.5.1 GSK: A Dominant Global Player
3.5.2 Expanding Vaccination Programmes in Emerging Markets
3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast 2012-2022
3.6 Hepatitis Treatment and Vaccine Submarket Shares 2011, 2016 and 2022
3.7 Hepatitis Treatment Market: Revenue Forecast by Indication 2012-2022
4. LEADING NATIONAL HEPATITIS TREATMENT AND VACCINE MARKETS 2012-2022
4.1 Global Prevalence of Hepatitis 2012
4.1.1 The Importance of Asia
4.2 Hepatitis Treatment and Vaccine Market: Regional Breakdown 2011
4.3 Hepatitis Treatment and Vaccine Market: Regional Forecast 2012-2022
4.4 The US
4.4.1 Population Movement and Hepatitis
4.4.2 Screening for Hepatitis
4.4.3 The US: Revenues 2012-2022
4.5 Europe
4.5.1 Regional Prevalence
4.5.2 European Market 2011
4.5.3 European Market: Revenue Forecasts 2012-2022
4.5.4 Italy: Revenues 2012-2022
4.5.5 Spain: Revenues 2012-2022
4.5.6 Germany: Revenues 2012-2022
4.5.7 UK: Revenues 2012-2022
4.5.8 France: Revenues 2012-2022
4.6 Hepatitis in Asia
4.7 China
4.7.1 Increased Vaccination
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenues 2012-2022
4.8 Japan
4.8.1 Hepatitis B and C in Japan
4.8.2 Japan: Revenues 2012-2022
4.9 India
4.9.1 Low Awareness and Vaccination Rates
4.9.2 India: Revenues 2012-2022
5. LEADING HEPATITIS THERAPIES: MARKET PROSPECTS TO 2022
5.1 Leading Hepatitis B Therapies 2012-2022
5.2 Baraclude (Bristol-Myers Squibb)
5.2.1 Recent Revenue Analysis
5.2.2 Patent Challenges
5.2.3 Baraclude: Revenue Forecast 2012-2022
5.3 Zeffix (GSK)
5.3.1 Recent Revenue Analysis
5.3.2 Resistance to Zeffix
5.3.3 Generic Competition
5.3.4 Zeffix: Revenue Forecast 2012-2022
5.4 Hepsera (Gilead Sciences/GSK)
5.4.1 Recent Revenue Analysis
5.4.2 Patent Expiry and Generic Competition
5.4.3 Switching to Viread
5.4.4 Hepsera: Revenue Forecast 2012-2022
5.5 Viread (Gilead Sciences)
5.5.1 Recent Revenue Analysis
5.5.2 GSK Licensing Agreement
5.5.3 Prodrugs in Development
5.5.4 Viread: Revenue Forecast 2012-2022
5.6 Tyzeka (Novartis)
5.6.1 Resistance and Competition
5.6.2 Tyzeka: Revenue Forecast 2012-2022
5.7 Leading Hepatitis B Vaccines 2012-2022
5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
5.8.1 Recent Revenue Analysis
5.8.2 Demand and Supply in Emerging Markets
5.8.3 Competition in the Pipeline
5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast 2012-2022
5.9 Leading Hepatitis C Therapies 2012-2022
5.10 Pegasys (Roche)
5.10.1 Recent Revenue Analysis
5.10.2 Label Expansions and Lifecycle Management
5.10.3 Pegasys: Revenue Forecast 2012-2022
5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
5.11.1 Revenue Analysis 2011
5.11.2 Possible Label Expansion
5.11.3 Incivek in Interferon-Free Regimens
5.11.4 Pipeline Competition
5.11.5 Incivek: Revenue Forecast 2012-2022
5.12 PegIntron (Merck & Co.)
5.12.1 Revenue Analysis 2011
5.12.2 Biosimilar Competition
5.12.3 Lifecycle Management
5.12.4 PegIntron: Revenue Forecast 2012-2022
5.13 Victrelis (Merck & Co.)
5.13.1 Revenue Analysis 2011
5.13.2 Roche Collaboration
5.13.3 Product Differentiation
5.13.4 Victrelis: Revenue Forecast 2012-2022
6. HEPATITIS TREATMENT AND VACCINE MARKET: LEADING PIPELINE CANDIDATES 2012
6.1 Leading Hepatitis C Pipeline Candidates 2012
6.1.1 Alisporivir (Novartis/Debiopharm)
6.1.2 BI 201335 (Boehringer Ingelheim)
6.1.2.1 BI 207127 (Boehringer Ingelheim)
6.1.3 Daclatasvir (Bristol-Myers Squibb)
6.1.3.1 Asunaprevir (Bristol-Myers Squibb)
6.1.4 GS-7977 (Gilead Sciences)
6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir)
6.1.5.1 TMC435 in All-Oral Regimens
6.1.6 Vaniprevir (Merck & Co.)
6.1.7 ABT-450 (Abbott Laboratories)
6.1.8 ACH-1625 (Achillion Pharmaceuticals)
6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals)
6.1.10 Danoprevir (Roche)
6.1.11 GI-5005 (GlobeImmune)
6.1.12 IDX184 (Idenix Pharmaceuticals)
6.1.13 INX-189 (Inhibitex)
6.1.14 Locteron (Biolex)
6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb)
6.1.16 R7128 (Roche/Pharmasset)
6.1.17 SCY-635
6.1.18 Setrobuvir (Roche)
6.1.19 Tegobuvir (Gilead Sciences)
6.1.20 VX-222 (Vertex Pharmaceuticals)
6.2 Leading Hepatitis B Pipeline Candidates 2012
6.2.1 Heplisav (Dynavax Technologies)
6.2.2 Rep 9AC' (REPLICor)
6.2.3 Myrcludex B (MYR)
6.2.4 AGX-1009 (Agenix)
7. LEADING COMPANIES IN HEPATITIS TREATMENT IN 2012
7.1 Leading Market Players, 2012
7.2 Roche
7.2.1 Product Overview and Performance 2011
7.2.2 Recent Developments
7.2.3 Hepatitis Pipeline
7.2.4 Future Outlook
7.3 GSK
7.3.1 Product Overview and Performance 2011
7.3.2 Recent Developments
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook
7.4 Bristol-Myers Squibb
7.4.1 Product Overview and Performance 2011
7.4.2 Recent Developments
7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook
7.5 Merck & Co.
7.5.1 Product Overview and Performance 2011
7.5.2 Recent Developments
7.5.3 Hepatitis Pipeline
7.5.4 Future Outlook
7.6 Vertex Pharmaceuticals
7.6.1 Product Overview and Performance 2011
7.6.2 Recent Developments
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook
7.7 Gilead Sciences
7.7.1 Product Overview and Performance 2011
7.7.2 Gilead Acquires Pharmasset
7.7.3 Hepatitis Pipeline
7.7.4 Future Outlook
7.8 Novartis
7.8.1 Product Overview and Performance 2011
7.8.2 Recent Developments
7.8.3 Hepatitis Pipeline
7.8.4 Future Outlook
7.9 Leading Hepatitis Pipeline Companies
7.9.1 Abbott Laboratories
7.9.2 Achillion Pharmaceuticals
7.9.2.1 Achillion and Gilead
7.9.3 Boehringer Ingelheim
7.9.4 Idenix Pharmaceuticals
7.9.4.1 Idenix Pharmaceuticals: Outlook
8. HEPATITIS TREATMENT AND VACCINE MARKET: INDUSTRY TRENDS 2012-2022
8.1 Strengths and Weaknesses in the Hepatitis Treatment and Vaccine Market 2011
8.1.1 Resistance in Hepatitis B
8.1.2 Interferon Therapy Has Drawbacks
8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis Treatment and Vaccine Market 2012-2022
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 Hepatitis B Vaccination
8.4 Limited Hepatitis B Pipeline
8.5 Hepatitis C Vaccines
8.6 Oral Direct-Acting Antivirals
8.6.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.6.2 Combining Protease and Polymerase Inhibitors
8.6.3 The Need for Ribavirin
8.6.4 Twelve Week Treatment Target
8.7 Pharmaceutical Investment in Hepatitis C
8.7.1 Licensing and Partnering Deals
8.7.2 Acquisitions in Hepatitis C
8.7.3 Future Targets for Collaboration or Acquisition
9. RESEARCH INTERVIEW
9.1 Dr David Spencer, CEO, Biotechnology Enterprise Management
9.1.1 Novel Interferon Development
9.1.2 Performance in a Competitive Market
9.1.3 Biosimilar Interferons
9.1.4 Opportunities and Threats in the Hepatitis C Market
10. CONCLUSIONS
10.1 State of the Hepatitis Treatment and Vaccine Market 2011
10.2 Growth in the Hepatitis Treatment and Vaccine Market 2012-2022
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Weak Pipeline for Hepatitis B
10.3 Asia as a Hepatitis Market
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2011
Table 1.2 Abbreviations and Acronyms Used in the Report
Table 2.1 Hepatitis Subtypes: An Overview
Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
Table 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
Table 3.2 Hepatitis Treatment Market by Indication, 2011
Table 3.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Sector, 2011-2022
Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2012
Table 3.5 Oral Antivirals Submarket: Drug Revenues, 2011
Table 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
Table 3.7 Interferons Submarket: Drug Revenues, 2011
Table 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
Table 3.9 Vaccines Submarket: Drug Revenues, 2011
Table 3.10 Vaccines Submarket: Revenue Forecast, 2011-2022
Table 3.11 Hepatitis Treatments and Vaccines: Submarket Shares, 2011, 2016 and 2022
Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts by Indication, 2011-2022
Table 4.1 Chronic Hepatitis B & C: Global Prevalence by Region, 2012
Table 4.2 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
Table 4.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Region, 2011-2022
Table 4.4 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.5 European Hepatitis Treatments and Vaccines: Market by Country, 2011
Table 4.6 European Hepatitis Treatment and Vaccine Market: Revenue Forecasts by Country, 2011-2022
Table 4.7 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.8 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.9 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.10 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.11 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.12 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.13 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.14 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 5.1 Baraclude: Key Facts, 2012
Table 5.2 Baraclude: Revenue by Region, 2009-2011
Table 5.3 Baraclude: Revenue Forecast, 2011-2022
Table 5.4 Zeffix: Key Facts, 2012
Table 5.5 Zeffix: Revenue by Region, 2010-2011
Table 5.6 Zeffix: Revenue Forecast, 2011-2022
Table 5.7 Hepsera: Key Facts, 2012
Table 5.8 Hepsera: Revenue by Company, 2009-2011
Table 5.9 Hepsera: Revenue Forecast, 2011-2022
Table 5.10 Viread: Key Facts, 2012
Table 5.11 Viread: Revenue Forecast, 2011-2022
Table 5.12 Tyzeka: Key Facts, 2012
Table 5.13 Tyzeka: Revenue, 2009-2011
Table 5.14 Tyzeka: Revenue Forecast, 2011-2022
Table 5.15 GSK's Hepatitis Vaccines: Key Facts, 2012
Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
Table 5.17 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
Table 5.18 Pegasys: Key Facts, 2012
Table 5.19 Pegasys: Revenue, 2009-2011
Table 5.20 Pegasys: Revenue Forecast, 2011-2022
Table 5.21 Incivek: Key Facts, 2012
Table 5.22 Incivek: Revenue by Region, 2011
Table 5.23 Incivek: Revenue Forecast, 2011-2022
Table 5.24 PegIntron: Key Facts, 2012
Table 5.25 PegIntron: Revenue Forecast, 2011-2022
Table 5.26 Victrelis: Key Facts, 2012
Table 5.27 Victrelis: Revenue Forecast, 2011-2022
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
Table 6.2 Alisporivir: Phase III Trials, 2012
Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
Table 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
Table 7.2 Roche: Hepatitis Clinical Pipeline, 2012
Table 7.3 Pegasys: Revenues and Market Share, 2011, 2016 and 2022
Table 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
Table 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
Table 7.7 Vertex Pharmaceuticals: Milestone Payments and Royalty Income for Telaprevir, 2004-2011
Table 7.8 Gilead Sciences: Revenue by Therapeutic Area, 2011
Table 7.9 Gilead Sciences: Hepatitis Clinical Pipeline, 2012
Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
Table 8.1 Hepatitis Treatment and Vaccine Market: Strengths and Weaknesses, 2011-2012
Table 8.2 Hepatitis Treatment and Vaccine Market: Opportunities and Threats, 2012-2022
Table 8.3 Liver Cancer: Global Deaths by Region, 2008
Table 8.4 Hepatitis: Global Deaths by Region, 2008
Table 8.5 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
Table 8.6 Selected All-Oral Hepatitis C Regimens in Development, 2012
Table 8.7 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
Table 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022
Table 10.2 Hepatitis Treatments: Patent Expiries & Peak Revenues, 2008-2025
Table 1.1 Currency Exchange Rates, 2011
Table 1.2 Abbreviations and Acronyms Used in the Report
Table 2.1 Hepatitis Subtypes: An Overview
Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
Table 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
Table 3.2 Hepatitis Treatment Market by Indication, 2011
Table 3.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Sector, 2011-2022
Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2012
Table 3.5 Oral Antivirals Submarket: Drug Revenues, 2011
Table 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
Table 3.7 Interferons Submarket: Drug Revenues, 2011
Table 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
Table 3.9 Vaccines Submarket: Drug Revenues, 2011
Table 3.10 Vaccines Submarket: Revenue Forecast, 2011-2022
Table 3.11 Hepatitis Treatments and Vaccines: Submarket Shares, 2011, 2016 and 2022
Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts by Indication, 2011-2022
Table 4.1 Chronic Hepatitis B & C: Global Prevalence by Region, 2012
Table 4.2 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
Table 4.3 Hepatitis Treatment and Vaccine Market: Overall Market and Revenue Forecasts by Region, 2011-2022
Table 4.4 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.5 European Hepatitis Treatments and Vaccines: Market by Country, 2011
Table 4.6 European Hepatitis Treatment and Vaccine Market: Revenue Forecasts by Country, 2011-2022
Table 4.7 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.8 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.9 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.10 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.11 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.12 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.13 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 4.14 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Table 5.1 Baraclude: Key Facts, 2012
Table 5.2 Baraclude: Revenue by Region, 2009-2011
Table 5.3 Baraclude: Revenue Forecast, 2011-2022
Table 5.4 Zeffix: Key Facts, 2012
Table 5.5 Zeffix: Revenue by Region, 2010-2011
Table 5.6 Zeffix: Revenue Forecast, 2011-2022
Table 5.7 Hepsera: Key Facts, 2012
Table 5.8 Hepsera: Revenue by Company, 2009-2011
Table 5.9 Hepsera: Revenue Forecast, 2011-2022
Table 5.10 Viread: Key Facts, 2012
Table 5.11 Viread: Revenue Forecast, 2011-2022
Table 5.12 Tyzeka: Key Facts, 2012
Table 5.13 Tyzeka: Revenue, 2009-2011
Table 5.14 Tyzeka: Revenue Forecast, 2011-2022
Table 5.15 GSK's Hepatitis Vaccines: Key Facts, 2012
Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
Table 5.17 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
Table 5.18 Pegasys: Key Facts, 2012
Table 5.19 Pegasys: Revenue, 2009-2011
Table 5.20 Pegasys: Revenue Forecast, 2011-2022
Table 5.21 Incivek: Key Facts, 2012
Table 5.22 Incivek: Revenue by Region, 2011
Table 5.23 Incivek: Revenue Forecast, 2011-2022
Table 5.24 PegIntron: Key Facts, 2012
Table 5.25 PegIntron: Revenue Forecast, 2011-2022
Table 5.26 Victrelis: Key Facts, 2012
Table 5.27 Victrelis: Revenue Forecast, 2011-2022
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
Table 6.2 Alisporivir: Phase III Trials, 2012
Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
Table 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
Table 7.2 Roche: Hepatitis Clinical Pipeline, 2012
Table 7.3 Pegasys: Revenues and Market Share, 2011, 2016 and 2022
Table 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
Table 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
Table 7.7 Vertex Pharmaceuticals: Milestone Payments and Royalty Income for Telaprevir, 2004-2011
Table 7.8 Gilead Sciences: Revenue by Therapeutic Area, 2011
Table 7.9 Gilead Sciences: Hepatitis Clinical Pipeline, 2012
Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
Table 8.1 Hepatitis Treatment and Vaccine Market: Strengths and Weaknesses, 2011-2012
Table 8.2 Hepatitis Treatment and Vaccine Market: Opportunities and Threats, 2012-2022
Table 8.3 Liver Cancer: Global Deaths by Region, 2008
Table 8.4 Hepatitis: Global Deaths by Region, 2008
Table 8.5 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
Table 8.6 Selected All-Oral Hepatitis C Regimens in Development, 2012
Table 8.7 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
Table 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022
Table 10.2 Hepatitis Treatments: Patent Expiries & Peak Revenues, 2008-2025
LIST OF FIGURES
Figure 2.1 A Brief History of Hepatitis, 1947-2012
Figure 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
Figure 3.2 Hepatitis Treatment Market by Indication, 2011
Figure 3.3 Hepatitis Treatment and Vaccine Market: Overall Market Forecast, 2011-2022
Figure 3.4 Oral Antivirals Submarket: Drug Revenues, 2011
Figure 3.5 Oral Antivirals Submarket: Drivers and Restraints, 2012-2022
Figure 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
Figure 3.7 Interferons Submarket: Drug Revenues, 2011
Figure 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
Figure 3.9 Interferons Submarket: Drivers and Restraints, 2012-2022
Figure 3.10 Vaccines Submarket: Drug Revenues, 2011
Figure 3.11 Vaccines Submarket: Drivers and Restraints, 2012-2022
Figure 3.12 Vaccines Submarket: Revenue Forecast, 2011-2022
Figure 3.13 Hepatitis Treatment and Vaccine Market by Sector, 2016
Figure 3.14 Hepatitis Treatment and Vaccine Market by Sector, 2022
Figure 3.15 Hepatitis B Submarket: Drivers and Restraints, 2012-2022
Figure 3.16 Hepatitis B Submarket: Revenue Forecast, 2011-2022
Figure 3.17 Hepatitis C Submarket: Drivers and Restraints, 2012-2022
Figure 3.18 Hepatitis C Submarket: Revenue Forecast, 2011-2022
Figure 4.1 Chronic Hepatitis B: Global Prevalence by Region, 2012
Figure 4.2 Chronic Hepatitis C: Global Prevalence by Region, 2012
Figure 4.3 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
Figure 4.4 Hepatitis Treatments and Vaccines: Market Shares by Region, 2016
Figure 4.5 Hepatitis Treatments and Vaccines: Market Shares by Region, 2022
Figure 4.6 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.7 European Hepatitis Treatments and Vaccines: Market by Country, 2011
Figure 4.8 European Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.9 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.10 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.11 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.12 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.13 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.14 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.15 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.16 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 5.1 Baraclude: Revenue by Region, 2009-2011
Figure 5.2 Baraclude: Revenue Forecast, 2011-2022
Figure 5.3 Zeffix: Revenue by Region, 2011
Figure 5.4 Zeffix: Revenue Forecast, 2011-2022
Figure 5.5 Hepsera: Revenue by Company, 2009-2011
Figure 5.6 Hepsera: Revenue Forecast, 2011-2022
Figure 5.7 Viread: Revenue Forecast, 2011-2022
Figure 5.8 Tyzeka: Revenue, 2009-2011
Figure 5.9 Tyzeka: Revenue Forecast, 2011-2022
Figure 5.10 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
Figure 5.11 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
Figure 5.12 Pegasys: Revenue, 2009-2011
Figure 5.13 Pegasys: Revenue Forecast, 2011-2022
Figure 5.14 Incivek: Revenue by Region, 2011
Figure 5.15 Incivek: Revenue Forecast, 2011-2022
Figure 5.16 PegIntron: Revenue Forecast, 2011-2022
Figure 5.17 Victrelis: Revenue Forecast, 2011-2022
Figure 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
Figure 7.2 Pegasys: Revenues, 2011, 2016 and 2022
Figure 7.3 Roche: Key Events in the Hepatitis Market, 2012-2022
Figure 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
Figure 7.5 Bristol-Myers Squibb: Key Events in the Hepatitis Market, 2012-2022
Figure 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
Figure 7.7 Gilead Sciences: Revenue by Therapeutic Area, 2011
Figure 7.8 Gilead Sciences: Key Events in the Hepatitis Market, 2012-2022
Figure 8.1 Liver Cancer: Global Deaths by Region, 2008
Figure 8.2 Hepatitis: Global Deaths by Region, 2008
Figure 8.3 All-Oral Regimens: Projected Launches, 2012-2016
Figure 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022
COMPANIES LISTED
3SBio
Abbott Laboratories
Abbott Molecular
Achillion Pharmaceuticals
Agenix
Alios BioPharma
American University in Cairo
Anadys Pharmaceuticals (now part of Roche)
Anhui Biochem Bio-Pharmaceutical
Apotex
Aurobindo Pharma
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Wantai Biological Pharmacy Enterprise
BioCryst Pharmaceuticals
Biogen Idec
Biolex
BioLineRx
BioPhausia (now part of Medivir)
Biota Holdings
Biotechnology Enterprise Management
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Centers for Disease Control and Prevention (CDC) [US]
China NT Pharma Group
Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
Chiron (now part of Novartis)
ChronTech Pharma
Chugai Pharmaceutical (part of Roche)
Codexis
Compass Biotechnologies
Corvas International (now part of Dendreon)
CPP Investment Board
Debiopharm
Dendreon
Drug Controller General of India (DCGI)
Dynavax Technologies
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
Enanta Pharmaceuticals
European Association for the Study of the Liver (EASL)
European Commission (EC)
European Liver Patients Association (ELPA)
European Medicines Agency (EMA)
Feron
Food and Drug Administration (FDA) [US]
Genelabs Technologies (now part of GSK)
Genoscience
Getz Pharma
Gilead Sciences
GlobeImmune
GSK
Hainan Zhonghe Pharmaceutical
Health Protection Agency (HPA) [UK]
Hepatera
High-Tech Grьnderfonds
Hualida Biotech
Idenix Pharmaceuticals
Imperial College London
Inhibitex (now part of BMS)
Inovio Pharmaceuticals
Institut de Veille Sanitaire (InVS) [France]
Institut fьr Qualitдt und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Institut National de la Santй et de la Recherche Mйdicale (INSERM) [France]
InterMune
J&J
Janssen Pharmaceutica (a subsidiary of J&J)
Kadmon Pharmaceuticals
Kun Run Biotechnology
LG Life Sciences
Maxwell Biotech Venture Fund
Medgenics
Medivir
Medtronic
Merck & Co.
Minapharm Pharmaceuticals
Ministry of Health [China]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
MYR
Nanogen Biopharmaceutical
Natco Pharma
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Novartis
OctoPlus
Okairos
Oxford University
Pharmasset (now part of Gilead)
Quest Diagnostics
Ranbaxy Laboratories
Reliance Life Sciences
REPLICor
Rhein Biotech (now part of Dynavax Technologies)
Roche
Sanofi Pasteur
Schering-Plough (now part of Merck & Co)
SciClone Pharmaceuticals
Scottish Medicines Consortium (SMC)
SCYNEXIS
Sigmapharm Laboratories
Sinopharm Group
State Food and Drug Administration (SFDA) [China]
Teva
The Vaccine Fund
Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
Transgene
University of Alberta
University of Heidelberg
Valeant Pharmaceuticals International
Vertex Pharmaceuticals
ViroChem Pharma (now part of Vertex)
Welsh School of Pharmacy (Cardiff University)
World Health Organization (WHO)
World Hepatitis Alliance
Xiamen Innovax Biotech
Xiamen University
Zuellig Pharma
Zydus Cadila
ZymoGenetics (now part of BMS)
Figure 2.1 A Brief History of Hepatitis, 1947-2012
Figure 3.1 Hepatitis Treatment and Vaccine Market by Sector, 2011
Figure 3.2 Hepatitis Treatment Market by Indication, 2011
Figure 3.3 Hepatitis Treatment and Vaccine Market: Overall Market Forecast, 2011-2022
Figure 3.4 Oral Antivirals Submarket: Drug Revenues, 2011
Figure 3.5 Oral Antivirals Submarket: Drivers and Restraints, 2012-2022
Figure 3.6 Oral Antivirals Submarket: Revenue Forecast, 2011-2022
Figure 3.7 Interferons Submarket: Drug Revenues, 2011
Figure 3.8 Interferons Submarket: Revenue Forecast, 2011-2022
Figure 3.9 Interferons Submarket: Drivers and Restraints, 2012-2022
Figure 3.10 Vaccines Submarket: Drug Revenues, 2011
Figure 3.11 Vaccines Submarket: Drivers and Restraints, 2012-2022
Figure 3.12 Vaccines Submarket: Revenue Forecast, 2011-2022
Figure 3.13 Hepatitis Treatment and Vaccine Market by Sector, 2016
Figure 3.14 Hepatitis Treatment and Vaccine Market by Sector, 2022
Figure 3.15 Hepatitis B Submarket: Drivers and Restraints, 2012-2022
Figure 3.16 Hepatitis B Submarket: Revenue Forecast, 2011-2022
Figure 3.17 Hepatitis C Submarket: Drivers and Restraints, 2012-2022
Figure 3.18 Hepatitis C Submarket: Revenue Forecast, 2011-2022
Figure 4.1 Chronic Hepatitis B: Global Prevalence by Region, 2012
Figure 4.2 Chronic Hepatitis C: Global Prevalence by Region, 2012
Figure 4.3 Hepatitis Treatments and Vaccines: Market Shares by Region, 2011
Figure 4.4 Hepatitis Treatments and Vaccines: Market Shares by Region, 2016
Figure 4.5 Hepatitis Treatments and Vaccines: Market Shares by Region, 2022
Figure 4.6 US Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.7 European Hepatitis Treatments and Vaccines: Market by Country, 2011
Figure 4.8 European Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.9 Italian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.10 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.11 German Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.12 UK Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.13 French Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.14 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.15 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 4.16 Indian Hepatitis Treatments and Vaccines: Submarket Forecast, 2011-2022
Figure 5.1 Baraclude: Revenue by Region, 2009-2011
Figure 5.2 Baraclude: Revenue Forecast, 2011-2022
Figure 5.3 Zeffix: Revenue by Region, 2011
Figure 5.4 Zeffix: Revenue Forecast, 2011-2022
Figure 5.5 Hepsera: Revenue by Company, 2009-2011
Figure 5.6 Hepsera: Revenue Forecast, 2011-2022
Figure 5.7 Viread: Revenue Forecast, 2011-2022
Figure 5.8 Tyzeka: Revenue, 2009-2011
Figure 5.9 Tyzeka: Revenue Forecast, 2011-2022
Figure 5.10 Engerix-B/Havrix/Twinrix/Fendrix: Revenue by Region, 2011
Figure 5.11 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2011-2022
Figure 5.12 Pegasys: Revenue, 2009-2011
Figure 5.13 Pegasys: Revenue Forecast, 2011-2022
Figure 5.14 Incivek: Revenue by Region, 2011
Figure 5.15 Incivek: Revenue Forecast, 2011-2022
Figure 5.16 PegIntron: Revenue Forecast, 2011-2022
Figure 5.17 Victrelis: Revenue Forecast, 2011-2022
Figure 7.1 Hepatitis Treatment and Vaccine Market by Company, 2011
Figure 7.2 Pegasys: Revenues, 2011, 2016 and 2022
Figure 7.3 Roche: Key Events in the Hepatitis Market, 2012-2022
Figure 7.4 GSK: Pharmaceutical Revenue by Therapeutic Area, 2011
Figure 7.5 Bristol-Myers Squibb: Key Events in the Hepatitis Market, 2012-2022
Figure 7.6 Merck & Co: Revenue by Therapeutic Area, 2011
Figure 7.7 Gilead Sciences: Revenue by Therapeutic Area, 2011
Figure 7.8 Gilead Sciences: Key Events in the Hepatitis Market, 2012-2022
Figure 8.1 Liver Cancer: Global Deaths by Region, 2008
Figure 8.2 Hepatitis: Global Deaths by Region, 2008
Figure 8.3 All-Oral Regimens: Projected Launches, 2012-2016
Figure 10.1 Hepatitis Treatment and Vaccine Market: Revenue by Drug & Sector, 2011, 2016 & 2022
COMPANIES LISTED
3SBio
Abbott Laboratories
Abbott Molecular
Achillion Pharmaceuticals
Agenix
Alios BioPharma
American University in Cairo
Anadys Pharmaceuticals (now part of Roche)
Anhui Biochem Bio-Pharmaceutical
Apotex
Aurobindo Pharma
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Wantai Biological Pharmacy Enterprise
BioCryst Pharmaceuticals
Biogen Idec
Biolex
BioLineRx
BioPhausia (now part of Medivir)
Biota Holdings
Biotechnology Enterprise Management
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Centers for Disease Control and Prevention (CDC) [US]
China NT Pharma Group
Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
Chiron (now part of Novartis)
ChronTech Pharma
Chugai Pharmaceutical (part of Roche)
Codexis
Compass Biotechnologies
Corvas International (now part of Dendreon)
CPP Investment Board
Debiopharm
Dendreon
Drug Controller General of India (DCGI)
Dynavax Technologies
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
Enanta Pharmaceuticals
European Association for the Study of the Liver (EASL)
European Commission (EC)
European Liver Patients Association (ELPA)
European Medicines Agency (EMA)
Feron
Food and Drug Administration (FDA) [US]
Genelabs Technologies (now part of GSK)
Genoscience
Getz Pharma
Gilead Sciences
GlobeImmune
GSK
Hainan Zhonghe Pharmaceutical
Health Protection Agency (HPA) [UK]
Hepatera
High-Tech Grьnderfonds
Hualida Biotech
Idenix Pharmaceuticals
Imperial College London
Inhibitex (now part of BMS)
Inovio Pharmaceuticals
Institut de Veille Sanitaire (InVS) [France]
Institut fьr Qualitдt und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Institut National de la Santй et de la Recherche Mйdicale (INSERM) [France]
InterMune
J&J
Janssen Pharmaceutica (a subsidiary of J&J)
Kadmon Pharmaceuticals
Kun Run Biotechnology
LG Life Sciences
Maxwell Biotech Venture Fund
Medgenics
Medivir
Medtronic
Merck & Co.
Minapharm Pharmaceuticals
Ministry of Health [China]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
MYR
Nanogen Biopharmaceutical
Natco Pharma
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Novartis
OctoPlus
Okairos
Oxford University
Pharmasset (now part of Gilead)
Quest Diagnostics
Ranbaxy Laboratories
Reliance Life Sciences
REPLICor
Rhein Biotech (now part of Dynavax Technologies)
Roche
Sanofi Pasteur
Schering-Plough (now part of Merck & Co)
SciClone Pharmaceuticals
Scottish Medicines Consortium (SMC)
SCYNEXIS
Sigmapharm Laboratories
Sinopharm Group
State Food and Drug Administration (SFDA) [China]
Teva
The Vaccine Fund
Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
Transgene
University of Alberta
University of Heidelberg
Valeant Pharmaceuticals International
Vertex Pharmaceuticals
ViroChem Pharma (now part of Vertex)
Welsh School of Pharmacy (Cardiff University)
World Health Organization (WHO)
World Hepatitis Alliance
Xiamen Innovax Biotech
Xiamen University
Zuellig Pharma
Zydus Cadila
ZymoGenetics (now part of BMS)
